Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p = .01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.
| Original language | English |
|---|---|
| Pages (from-to) | 1-6 |
| Number of pages | 6 |
| Journal | Leukemia and Lymphoma |
| DOIs | |
| Publication status | Accepted/In press - 2017 Oct 16 |
Fingerprint
Keywords
- allogeneic
- chronic myelomonocytic leukemia
- Cytogenetics
- hematopoietic stem transplantation
- prognosis
- scoring system
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia. / for the Kanto Study Group for Cell Therapy (KSGCT).
In: Leukemia and Lymphoma, 16.10.2017, p. 1-6.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia
AU - for the Kanto Study Group for Cell Therapy (KSGCT)
AU - Motohashi, Kenji
AU - Fujisawa, Shin
AU - Doki, Noriko
AU - Kobayashi, Takeshi
AU - Mori, Takehiko
AU - Usuki, Kensuke
AU - Tanaka, Masatsugu
AU - Fujiwara, Shinichiro
AU - Kako, Shinichi
AU - Aoyama, Yasuyuki
AU - Onoda, Masahiro
AU - Yano, Shingo
AU - Gotoh, Moritaka
AU - Kanamori, Heiwa
AU - Takahashi, Satoshi
AU - Okamoto, Shinichiro
PY - 2017/10/16
Y1 - 2017/10/16
N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p = .01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.
AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p = .01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.
KW - allogeneic
KW - chronic myelomonocytic leukemia
KW - Cytogenetics
KW - hematopoietic stem transplantation
KW - prognosis
KW - scoring system
UR - http://www.scopus.com/inward/record.url?scp=85031490839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031490839&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1387913
DO - 10.1080/10428194.2017.1387913
M3 - Article
SP - 1
EP - 6
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
ER -